Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Verona, New Jersey Clinical Trials

A listing of Verona, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (99) clinical trials

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

The goal of asthma treatment is to achieve and maintain asthma control and to reduce the future risk of exacerbations. Inhaled corticosteroids (ICS) are considered as the most effective anti- inflammatory treatment for all severities of persistent asthma. For children >=5 years of age and adolescents whose asthma is uncontrolled, …

Phase

0.41 miles

Learn More »

Long-Term PF-06651600 for the Treatment of Alopecia Areata

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as …

Phase

0.41 miles

Learn More »

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

This is a multi-center, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.

Phase

0.41 miles

Learn More »

Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to …

Phase

2.31 miles

Learn More »

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.

Phase

3.64 miles

Learn More »

A Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the Renexus implants in participants with macular telangiectasia type 2.

Phase

3.64 miles

Learn More »

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Following a 4-week maximum screening period, patients will be randomized and treated for approximately 76 weeks. Treatment visits will be scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading phase), subjects will enter a one-year individualized flexible treatment (IFT) phase. During the IFT phase, an …

Phase

3.64 miles

Learn More »

Cellular Immunotherapy in Recipients of HLA-matched Living Donor Kidney Transplants

Currently, patients receiving a transplanted kidney are required to take life-long immunosuppressive medications to prevent rejection of the transplanted kidney. These medications carry substantial side effects. In addition, these medicines often do not completely control damage to the kidney from the recipients' immune system, ultimately causing the kidney to fail. …

Phase

4.27 miles

Learn More »

A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2)

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe AD who are candidates for systemic therapy.

Phase

4.74 miles

Learn More »

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus …

Phase

4.77 miles

Learn More »